-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Sage Therapeutics has announced its potential "first-in-class" NMDA receptor allosteric modulator, SAGE-718, for the treatment of patients with mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease (AD).
In the study, 26 patients were treated with SAGE-718 for 14 days and a comprehensive panel of tests was used to assess multiple domains of their cognitive abilities
A statistically significant improvement in the Montreal Cognitive Assessment Scale (MoCA) was observed on day 28 (increase of 2.
SAGE-718 was generally well tolerated in this study
"Alzheimer's is one of the disease areas with the greatest unmet patient need, with an estimated global prevalence of more than 134 million people, with few treatment options specifically for mild cognitive impairment and mild dementia
References:
[1] Sage Therapeutics Announces Presentation of Promising Results from the Phase 2 LUMINARY Study of SAGE-718 in Patients with Mild Cognitive Impairment and Mild Dementia due to Alzheimer's Disease.
Original title: Express | The treatment of Alzheimer's disease, the potential "first-in-class" NMDA modulator Phase 2 clinical results are positive
